Gantacurium

Gantacurium
Claudio Melloni
l.p.
Già Direttore UO Anestesia e Rianimazione Ospedale di
Faenza
Consulente di anestesia per l’Azienda Ausl di Ravenna e
l’Ospedale privato accreditato Villa Torri,Bologna
Servizio di Anestesia e Rianimazione Ospedale di Faenza(RA)

Table 4


Table 7


esponse to increasing doses of GW280430A. Responses from each animal were subje

ery of tibialis anterior twitch after cessation of a 90-min infusion of GW280430A at a


age maximum change from baseline mean arterial pressure is small for doses through
mont: Anesthesiology, Volume 100(4).April 2004.768-773


Average maximum change from baseline heart rate increases as dose goes above 0.45
Belmont: Anesthesiology, Volume 100(4).April 2004.768-773


imum changes in heart rate (HR) and mean arterial pressure (MAP) for individuals re
olume 100(4).April 2004.768-773


Fig. 1
Fig. 1. The mean maximal heart rate (HR) and blood pressure changes
after bolus administration of GW280430A2 and mivacurium.5 Decreases
in mean arterial pressure (MAP) and increases in HR occur at doses of
2.5 times the ED95 of mivacurium. An average increase in HR of 7%
occurs with administration of 2.8 times the ED95 of GW280430A, and
an average increase of 14% occurs after administration of 3.8 times the
ED95 of GW280430A. Decreases in MAP occurred at a dose of 3.8
times the ED95. The average maximal decrease at this dose of
GW280430A was 18%. At all doses, GW280430A was administered as a
bolus (5 s) into a rapidly flowing intravenous line. In the study of
mivacurium,5 the neuromuscular blocking agent was injected three
times more slowly (15 s).
From: Lien: Anesthesiology, Volume 102(4).April 2005.861-862


3.8 times the ED95. The average maximal decrease at this dose of GW280430
From: Lien: Anesthesiology, Volume 102(4).April 2005.861-862


Table 8


Gantacurium

More Related Content

More from Claudio Melloni

Gantacurium